loading page

Effectiveness of XBB.1.5 monovalent COVID-19 vaccines during a period of XBB.1.5 dominance in EU/EEA countries, October to November 2023
  • +18
  • Susana Monge,
  • James Humphreys,
  • Nathalie Nicolay,
  • Toon Braeye,
  • Izaak Van Evercooren,
  • Christian Holm Hansen,
  • Hanne-Dorthe Emborg,
  • Chiara Sacco,
  • Alberto Mateo Urdiales,
  • Jesus Castilla,
  • Iván Martínez-Baz,
  • Brechje de Gier,
  • Susan Hahné,
  • Hinta Meijerink,
  • Anja Bråthen Kristoffersen,
  • Ausenda Machado,
  • Patricia Soares,
  • Anthony Nardone,
  • Sabrina Bacci,
  • Esther Kissling,
  • Baltazar Nunes
Susana Monge
Instituto de Salud Carlos III

Corresponding Author:smonge@isciii.es

Author Profile
James Humphreys
Epiconcept SAS
Author Profile
Nathalie Nicolay
European Centre for Disease Prevention and Control
Author Profile
Toon Braeye
Sciensano
Author Profile
Izaak Van Evercooren
Sciensano
Author Profile
Christian Holm Hansen
Statens Serum Institut
Author Profile
Hanne-Dorthe Emborg
Statens Serum Institut
Author Profile
Chiara Sacco
Istituto Superiore di Sanita
Author Profile
Alberto Mateo Urdiales
Istituto Superiore di Sanita
Author Profile
Jesus Castilla
Instituto de Salud Publica y Laboral de Navarra
Author Profile
Iván Martínez-Baz
Instituto de Salud Publica y Laboral de Navarra
Author Profile
Brechje de Gier
Rijksinstituut voor Volksgezondheid en Milieu
Author Profile
Susan Hahné
Rijksinstituut voor Volksgezondheid en Milieu
Author Profile
Hinta Meijerink
Folkehelseinstituttet
Author Profile
Anja Bråthen Kristoffersen
Folkehelseinstituttet
Author Profile
Ausenda Machado
Instituto Nacional de Saude Doutor Ricardo Jorge
Author Profile
Patricia Soares
Instituto Nacional de Saude Doutor Ricardo Jorge
Author Profile
Anthony Nardone
Epiconcept SAS
Author Profile
Sabrina Bacci
European Centre for Disease Prevention and Control
Author Profile
Esther Kissling
Epiconcept SAS
Author Profile
Baltazar Nunes
Epiconcept SAS
Author Profile

Abstract

Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in ≥65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted Hazard Ratios and derive VE. VE for COVID-10 hospitalisation and death was, respectively, 67% (95%CI: 60-72) and 68% (95%CI: 44-82) in 65–79-year-olds, and 64% (95%CI: 49-75) and 74% (95%CI: 56-85) in ≥80-year-olds. Results indicate that periodic vaccination of individuals ≥65 years has an ongoing benefit, and support the current vaccination strategies in the EU/EEA.
14 Mar 2024Submitted to Influenza and other respiratory viruses
18 Mar 2024Submission Checks Completed
18 Mar 2024Assigned to Editor
20 Mar 2024Reviewer(s) Assigned
20 Mar 2024Review(s) Completed, Editorial Evaluation Pending
20 Mar 2024Editorial Decision: Revise Minor
22 Mar 2024Submission Checks Completed
22 Mar 2024Assigned to Editor